<DOC>
	<DOCNO>NCT01979341</DOCNO>
	<brief_summary>The use antagonist control ovarian stimulation protocol allow use GnRH agonist use final oocyte maturation . The use GnRH agonist ovulation trigger show reduce risk ovarian hyperstimulation syndrome ( OHSS ) , sole use result reduce embryo implantation due luteal phase insufficiency . The combination GnRH agonist variable dos hCG final oocyte maturation show overcome luteal phase insufficiency effect endometrial receptivity . In study investigator test hypothesis use GnRH agonist ( 0.2mg Triptorelin ) full dose hCG ( 6500IU Ovitrelle ) final oocyte maturation normoresponders increase oocyte maturity , embryo quality embryo implantation reduce ovarian hyperstimulation syndrome , compare traditional hCG ( full dose ) alone trigger .</brief_summary>
	<brief_title>The Effect Dual Trigger Intracytoplasmic Sperm Injection ( ICSI ) Reproductive Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Age ; &lt; 40 year Cycle number ; cycle 1 2 Antral follicle count ; &gt; 10 &lt; 25 BMI ; &gt; 18 &lt; 30 Normogonadotrophic cycle length ; 24 25 day Male ; ejaculate semen Presence endocrine disorder ; ( diabetes mellitus , hyperprolactinemia , thyroid dysfunction , congenital adrenal hyperplasia , Cushing syndrome , polycystic ovary syndrome ) Previous major uterine surgery ( would affect endometrial receptivity ) Secondary exclusion criterion &lt; 5 follicle time trigger &lt; 2 full form blastocyst day 5 embryo culture</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>dual trigger</keyword>
	<keyword>hCG</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>ICSI</keyword>
	<keyword>pregnancy</keyword>
	<keyword>OHSS</keyword>
</DOC>